Pneumococcal Pneumonia Vaccine Research Study
Researchers at the University of Alabama at Birmingham are conducting a study to compare a 21-valent pneumococcal disease vaccine to the FDA-approved 20-valent pneumococcal disease vaccine.
Fast Facts
Generally healthy (no significant neurological diseases or medical illnesses)
2-17 Years Old
No Vaccines in the Last 2 Weeks
Compensation Provided
Conducted in Birmingham, AL
Study Background
Researchers at the University of Alabama at Birmingham are conducting a study to compare a 21-valent pneumococcal disease vaccine to the FDA-approved 20-valent pneumococcal disease vaccine for infants, toddlers, children and adolescents.
Study Background
Researchers at the University of Alabama at Birmingham are conducting a study to compare a 21-valent pneumococcal disease vaccine to the FDA-approved 20-valent pneumococcal disease vaccine for infants, toddlers, children and adolescents.
Pneumococcal disease is known to cause serious complications for children under five years old, and vaccination remains a crucial preventive measure. There are more than 100 pneumococcal variants, which requires the need for a more robust and durable vaccine protection.
Our study team aims to understand the safety and immunogenicity of the study vaccine when compared to the Prevnar 20 vaccine. Half of participants will receive the study vaccine and half the participants will receive the Prevnar 20 vaccine. The study is modified double-blinded, which means both the study team and the families participating will not know which vaccine the child received.
Join our study today to help the study of an updated pnuemococcal pneumonia vaccine!
Additional Information
The study is designed to collect data about the safety and immunogenicity of the experimental vaccine for infants, toddlers, children, and adolescents.
You or your child may qualify for a study if the following criteria are met:
Inclusion Criteria:
- Ages 2-17
- Generally healthy (no significant neurological diseases or medical illnesses)
Exclusion Criteria:
-
Received a vaccine in the last 2 weeks
-
Ever received the pneumococcal polysaccharide vaccine.
-
Pregnant or breastfeeding
If a participant is enrolled in this study, they/their legal guardian will be asked to sign the consent form. The participant will then be randomized to receive either PCV21 (the study vaccine) or Prevnar 20.
There are 2 in-person visits and 2 telephone calls over a period of 7 months. The participant/legal guardian will be asked to keep a study diary.
There will only be 1 injection for the 2-17 years age group.
Participant will receive compensation for each in-person visit, telephone visit, and weekly study diary completion.
There is no cost for you to participate in our research study.